Shakhsi Niaee, Morteza and Namdar, Peyman and Allami, Abbas and Zolghadr, Leila and Javadi, Amir and Karampour, Amin and Varnaseri, Mehran and Bijani, Behzad and Cheraghi, Fatemeh and Naderi, Yazdan and Amini, Fatemeh and Karamyan, Masoumeh and YadYad, Mohammad Jafar and Jamshidian, Ramin and Gheibi, Nematollah (2021) Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. Asian Pacific Journal of Tropical Medicine, 14 (6). pp. 266-273.
![[img]](http://eprints.qums.ac.ir/style/images/fileicons/application_pdf.png) |
PDF
Download (678kB) |
Abstract
Objective: To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences. Methods: A randomized, double-blind, placebo-controlled, multicenter clinical trial was performed at five hospitals. A total of 180 mild hospitalized patients with COVID-19 confirmed by PCR or chest image tests were enrolled and allocated to six arms including hydroxychloroquine 200 mg twice per day, placebo plus hydroxychloroquine 200 mg twice per day, single dose ivermectin (200 µg/kg), three low interval doses of ivermectin (200, 200, 200 µg/kg), single dose ivermectin (400 µg/kg), and three high interval doses of ivermectin (400, 200, 200 µg/kg). The primary endpoint of this trial was all-cause of mortality or clinical recovery. The radiographic findings, hospitalization and low O2 saturation duration, and hematological variables of blood samples were analyzed. Results: A total of 16.7% (5/30) and 20.0% (6/30) patients died in arms treated with hydroxychloroquine 200 mg twice per day and placebo plus hydroxychloroquine 200 mg twice per day, respectively, and a reduction in mortality rate in patients receiving ivermectin treatment to 0%, 10%, 0% and 3.3% for arms 1-4 were observed. Risk of mortality was also decreased about 15% in the ivermectin treated arms. Conclusions: Ivermectin as an adjunct reduces the rate of mortality, time of low O2 saturation, and duration of hospitalization in adult COVID-19 patients. The improvement of other clinical parameters shows that ivermectin, with a wide margin of safety, had a high therapeutic effect on COVID-19.
| Item Type: | Article |
|---|---|
| Subjects: | R Medicine > RP Paramedical > RP105 Biotechnology R Medicine > RS Pharmacy and materia medica |
| Divisions: | University Portal > vice chancellor > vcr |
| Depositing User: | Mrs Shahrzad Gholami |
| Date Deposited: | 13 Sep 2021 05:45 |
| Last Modified: | 13 Sep 2021 05:45 |
| URI: | http://eprints.qums.ac.ir/id/eprint/11028 |
Actions (login required)
 |
View Item |
